Raleigh biotech developing therapeutics for migraine and other headache disorders. Lead program SLTE-1009 is a subcutaneous anti-PACAP monoclonal antibody in-licensed from DartsBio Pharmaceuticals, targeting a pathway distinct from CGRP.
At a glance
- Founded: 2024
- HQ: Raleigh
- Sector: Biotech
- Stage: Series A
- Total raised: $130M
- Last round: Series A
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on Slate Medicines · last checked Oct 1, 2026
Overview
Raleigh-based biotech launched 2026-02-24. Incubated with RA Capital's Raven healthcare incubator; led by CEO Gregory Oakes (formerly CEO of Landos Biopharma, acquired by AbbVie). President and COO Neil Buckley is Raleigh-based.
Lead asset
SLTE-1009, an anti-PACAP monoclonal antibody in-licensed from China's DartsBio Pharmaceuticals for the prevention of migraine and other headache disorders. Cleared to begin Phase 1 in Australia with initial data expected mid-2027.
Funding
$130M Series A led by RA Capital Management with Forbion, Foresite Capital, and an undisclosed biotech investor. Per Triangle Business Journal (2026-08-17), pursuing a Nasdaq listing (ticker SLTE) via reverse merger with Fulcrum Therapeutics, expected to close in the fourth quarter of 2026, with a $245M private placement led by Frazier Life Sciences (Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, and Mingxin participating); securities filings cited by TBJ value Slate at $350M.
Listed roles
All Triangle rolesChecking listed roles…